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Abstract 
Elevated homocysteine levels are associated with increased risk of heart disease.  One possible 
strategy to reduce risk of heart disease is through reduction of homocysteine with vitamin B.  
Eighty middle-aged men and women participated in a four-week study examining vitamin 
supplementation effects.  Pre-test measures consisted of the Beck Depression Inventory, Revised 
Life Orientation Test, Cohen’s Perceived Stress Scale, and an assessment of homocysteine.  
Post-test measures included the same battery of tests as well as the Profile of Mood States.  
Participants were randomly assigned to receive either the self-administered supplement 
consisting of 0.4 mg folate, 0.4 mg B12, and 10 mg B6 or a placebo. Data were analyzed with 
repeated measures analysis of variance with time (pre-test v. post-test) as a within-subjects factor 
and condition (vitamin v. placebo) as a between-subjects factor.  With an alpha level of 0.05, no 
statistically significant effect of supplementation was found for depression, F (1, 80) = 2.27, p = 
0.14 or homocysteine, F (1, 80) = 0.80, p = 0.37. 
Vitamin Supplementation Effects on 
Homocysteine and Psychological Functioning 
High rates of coronary heart disease (CHD) have piqued researchers’ interests in 
examining mechanisms within the body that contribute to CHD development.  According to 
recent statistics from the American Heart Association (2005), 13 million people in the US in 
2005 were diagnosed with heart disease and it is the primary cause of death and permanent 
premature disability.  Also, $393.5 billion was the 2005 estimate for medical expenses and lost 
productivity due to heart disease. Because of the high cost of CHD for society, present and 
future research should focus on prevention of heart disease development. 
Interest in metabolic factors affecting the heart was initiated with the observation that 
individuals with malfunctioning metabolism had higher homocysteine (Hcy) levels and higher 
rates of atherosclerosis and premature death than the normal population (McCully, 1969).  
Following this observation, several studies investigated possible relationships between Hcy and 
other known risk factors for CHD development, including older age and elevated blood pressure 
(Schaefer, 2002; Nygard et al., 1995).  The role of Hcy in heart problems like myocardial 
infarction (MI) and stroke was further investigated (Nygard et al., 1997).  It was hypothesized 
that elevated Hcy levels increase vulnerability to atherosclerosis, which is the first step in 
developing heart disease. Although the actual mechanism of Hcy increasing CHD risk is 
unclear, past research has shown that Hcy and CHD risk are positively correlated (Zylberstein et 
al., 2004; Whincup et al., 1999). As a result, factors affecting Hcy were investigated with a few 
researchers focusing on the relationship between B vitamins and Hcy (Hvas, Ellegaard, & Nexo, 
2001; Lee et al., 2004). The general finding has been that deficiency of B vitamins, specifically 
B12 and folic acid, lead to increases in Hcy.  This increase in Hcy is due to the body’s inability to 
metabolize Hcy.  Paul, McDonnell, and Kelly (2004) established vitamin B as one of the primary 
factors in Hcy metabolism.   
In addition to the previously found influence of vitamin deficiency on physical health, 
Penninx et al. (2000) found that vitamin B12 deficiency is associated with a two-fold increased 
risk of severe depression. Baldewicz et al. (2000) also found that vitamin B12 is inversely related 
to self-report measures of distress and clinically rated depressed mood.  Lower folate levels were 
also associated with depression (Fava et al., 1997).   
Studies have found that depression is a significant risk factor for CHD morbidity and 
mortality after MI (Carney & Freedland, 2003).  Suls and Bunde (2005) found that anxiety and 
depression play a role in exacerbating the physical process of development of heart disease.  In 
2000, Frasure-Smith et al. found that depression was associated with a 3 to 4-fold increase in 
cardiac mortality.  Frasure-Smith and Lespérance (2005) then stated that depression is 
associated with at least a doubling in risk of mortality and recurrent cardiac events in patients 
with CHD. However, the causal relationship between depression and CHD is not known due to 
many possible mechanisms leading to either disease.  Despite the inexplicable mechanisms 
behind the two diseases, there is growing support that depression is associated with increased 
risk of cardiac events in people with CHD as well as development of CHD in healthy 
individuals. 
Earlier studies have shown that B vitamins, Hcy, and psychological functioning are inter­
related. However, the relationship between Hcy and psychological functioning has not been 
studied extensively. In order to assess the relationship between psychological functioning and 
Hcy, measures of depression, stress, optimism, and distress were used to define psychological 
functioning. It was hypothesized that dietary supplementation with B vitamins would improve 
psychological health and reduce Hcy. Also, lower psychological distress was hypothesized to be 
associated with lower Hcy levels.     
Methods 
Sample 
 Participant demographics.  Eighty local Columbus residents (37 men, 43 women, mean 
age = 39 years) were recruited through the use of flyers and advertisements directed toward the 
Ohio State University (OSU) campus and Columbus community.  Volunteers were screened for 
eligibility and healthy individuals were asked to participate in the study.  A $300 payment given 
to participants upon completion of the study was made possible by the NIH.   
Eligibility criteria.  General health of individuals interested in participating was 
determined during a brief telephone screening of the volunteers.  Men and women taking 
medication for diabetes, hypertension, or CHD were ineligible to participate.  Individuals 30 % 
over or under their ideal body weight, with renal disease or other metabolic diseases, severely 
depressed, taking vitamin or herbal supplements were also ineligible.  Discontinuation of vitamin 
or herbal supplements for the duration of the study allowed volunteers to become eligible for the 
study. In addition to these criteria, women were required to be premenopausal and have normal 
menstrual cycles.  Women who were pregnant, nursing, or taking oral contraceptives within the 
past six months were ineligible to participate. 
Design 
A 2 (vitamin v. placebo) x 2 (pre-test v. post-test) factorial design was used to measure 
the influence of vitamin supplementation on Hcy levels during the month-long intervention.   
Apparatus 
 Physiological measures. Hcy was measured using high performance liquid 
chromatography (HPLC) with fluorescence.  Serum folate was measured using the ADVIA 
Centaur System.  Serum B12 was measured with the Magnetic Separation Immunoassay.  Plasma 
B6 was measured using HPLC with electrochemical detection.  Total cholesterol, triglyceride 
levels, and high and low density lipoproteins were also measured.  Heart rate and blood pressure 
data were collected as well. 
Psychological measures.  Several scales were used to evaluate psychological functioning.  
The Beck Depression Inventory (BDI) is a measure of current affective, cognitive, and 
physiological symptoms of depression for both normal and clinical populations (Beck, Steer, & 
Garbin, 1988). Cohen’s Perceived Stress Scale (PSS-10) is useful in measuring the degree to 
which individuals perceive the environment and their experiences as stressful.  The PSS-10 has 
shown sensitivity to ongoing life circumstances, and is a valid measure of vulnerability to stress 
(Cohen, 1988). The Revised Life Orientation Test (LOT-R) is an internally consistent measure 
of an individual’s general outlook on life and level of optimism (Scheier, Carver, & Bridges, 
1994). The Profile of Mood States (POMS) measures total mood disturbance consisting of 
different subscales that measure changes in levels of anxiety, depression, anger, vigor, fatigue, 
and confusion (McNair, Lorr, & Droppleman, 1971).  All measures for the study have been 
shown to have acceptable to high reliability and validity in indicating psychological health.   
Procedure 
Pre-test.  All prospective participants completed a telephone screening regarding 
information about the participant’s diet, vitamin or herbal intake, and medication.  If eligibility 
criteria were met, a meeting was scheduled to begin participation in the study.  Directions and a 
map of OSU, along with contact information and a parking voucher were mailed to the 
participant.  The participant met with the investigator and on-site nutritionist on the scheduled 
date who informed him or her about the risks and benefits of participation in the study.  The 
participant was randomly assigned to either the vitamin or placebo condition after consenting to 
participate. At that time, the BDI, LOT-R, and PSS-10 were completed.  Blood was drawn to 
measure total Hcy.  The vitamin or placebo supplements were given to the participant and a 
follow-up phone call before the next session was used as a reminder for regular supplement 
intake. Participants were required to take the supplements daily for four weeks.  Vitamin group 
participants were given supplements consisting of 0.4 mg folate, 0.4 mg vitamin B12, and 10 mg 
vitamin B6. Placebo group participants received supplements consisting of cornstarch that were 
similar to the vitamins in size and tendency to discolor urine.  Discoloration of urine is one of the 
effects of vitamin supplements and was a necessary effect for placebo supplements to duplicate.  
Participants were instructed to hold a 12-hour fast before the final session. 
Post-test.  The participant met with the investigator and nutritionist for the post-test four 
weeks after the initial session. The BDI, LOT-R, PSS-10, and POMS were completed during the 
final session. Blood was drawn to measure total Hcy.  The participant was dismissed and mailed 
$300 for completion of the study. 
Data Analyses 
Correlational analyses were performed to assess the relationship between B vitamins, 
Hcy, and psychological functioning.  Repeated measures analysis of variance (ANOVA) was 
used to assess change in Hcy, psychological functioning, and B vitamins over time.  For the 
repeated measures ANOVA, time (pre-test v. post-test) was a within-subject variable and 
condition (vitamin v. placebo) was a between subject variable. 
Results 
 Correlational analyses indicated a modest correlation (r = 0.24, p = 0.03) between pre­
test BDI scores and Hcy of all participants. LOT-R and PSS-10 scores were not associated with 
Hcy. Simple descriptive analyses showed that participants with elevated depression scores (i.e. 
BDI scores of 10 or greater) had a mean Hcy level of MD = 10.31 while non-depressed 
participants had a mean Hcy level of MN  = 7.98 as shown in Figure 1.  Analysis of variance 
(ANOVA) indicated that the difference in pre-test Hcy levels of depressed and non-depressed 
participants was significant, F (1, 80) = 6.29, p = 0.01. Pre-test ANOVA of Hcy levels indicated 
no difference between vitamin group participants (mean Hcy level of MV  = 8.15) and placebo 
group participants (mean Hcy level of MP = 8.72) as shown in Table 1, F (1, 80) = 0.55, p = 0.46. 
Pre-test BDI scores were then analyzed and results showed no difference in BDI scores based on 
condition. Vitamin group participants had a mean BDI score of MV = 5.85 while placebo group 
participants had a mean of MP = 5.68, as shown in Table 1 and Figure 2, F (1, 80) = 0.02, p = 
0.90. Pre-test ANOVA of folate levels revealed no difference between vitamin group 
participants (mean folate level of MV = 19.57) and placebo group participants (mean folate level 
of MP = 18.85) as shown in Table 1, F (1, 80) = 0.35, p = 0.56. Pre-test ANOVA of vitamin B6 
and vitamin B12 based on condition also revealed no difference between participants’ vitamin 
levels. Refer to Table 1 for means and standard deviations for vitamin B6 and vitamin B12. 
Repeated measures ANOVA for Hcy revealed no interaction of time by condition, F (1, 
80) = 0.80, p = 0.37, but a time main effect for Hcy occurred regardless of condition, F (1, 80) = 
15.34, p = 0.00. Hcy levels of vitamin and placebo group participants decreased over time as 
shown in Table 1. Note that although Hcy levels of all participants decreased, vitamin group 
participants’ Hcy levels decreased somewhat more than Hcy levels of placebo group participants.  
Repeated measures ANOVA for depression scores revealed no effect of time or group, F (1, 80) 
= 2.27, p = 0.14. As shown in Table 1 and Figure 2, BDI scores of vitamin group participants 
decreased, but BDI scores of placebo group participants increased. Neither of these changes was 
statistically significant. Repeated measures ANOVA of folate, vitamin B6, and vitamin B12 
between session 1 and session 3 revealed no time by condition interaction.  However, time main 
effects were found for all vitamins:  folate, F (1, 80) = 5.67, p = 0.02; vitamin B12, F (1, 80) = 
13.72, p = 0.00; and vitamin B6, F (1, 80) = 20.58, p < 0.00. Repeated measures ANOVA with 
participants divided into depressed and non-depressed groups indicated a time main effect for 
Hcy, F (1, 80) = 0.14, p = 0.71. Simple effects indicated that Hcy levels of participants with 
elevated depression scores experienced a somewhat larger reduction in Hcy levels (mean Hcy of 
MD at post-test = 7.53) compared to non-depressed participants (mean Hcy of MN  at post-test = 
7.82), as shown in Figure 1. Post-test correlational analyses revealed that BDI, LOT-R, and 
PSS-10 scores were not associated with Hcy. However, POMS scores were found to be 
moderately associated with Hcy (r = 0.23, p = 0.04). 
Discussion 
The study was designed to evaluate the effect of dietary supplementation with B vitamins 
on psychological functioning and Hcy. Another goal of the study was to evaluate the 
relationship between psychological functioning and Hcy.  Although the results were statistically 
non-significant, the changes observed generally supported the hypotheses. 
The association of BDI scores and Hcy levels supports the idea that psychological 
functioning and Hcy are related. However, after treatment, BDI was no longer associated with 
Hcy, but POMS was better correlated with Hcy, which suggests that global distress was a better 
indicator of psychological functioning as it relates to Hcy instead of depression.  This finding is 
probably due to the fact that POMS measures a wider range of psychological functions than the 
BDI. Unfortunately, the POMS was not administered at baseline.  Future studies should consider 
administering the POMS during pre-test analyses in order to have stronger support for its 
association with Hcy as a measure of psychological functioning.  LOT-R and PSS-10 scores had 
almost non-existent correlations with Hcy, indicating that optimism and perceived stress were 
not related to Hcy. Optimism was not expected to respond to the vitamin intervention because it 
is a generally stable measure of personality functioning.  Perceived stress, however, was 
expected to be responsive to the vitamin intervention.  Also, because stress results in 
physiological manifestations in the body, stress could have a greater effect on Hcy.  However, 
the PSS-10 data indicated that participants were not experiencing significant distress. 
Of greatest interest were results indicating a time main effect for Hcy.  Two analyses of 
Hcy were performed and both found that Hcy decreased regardless of condition (vitamin v. 
placebo) or psychological health (depressed v. not depressed). Although it would have been 
ideal to find that Hcy decreased only for vitamin group participants, the Hcy decrease observed 
in all participants is also a favorable result.  This could indicate that time alone could decrease 
Hcy. However, because the vitamin group experienced a somewhat larger reduction in Hcy than 
the placebo group, this could still be an indication that vitamin supplementation has a stronger 
effect on Hcy than time alone.  Although this was the case, it cannot be concluded that treatment 
was the cause for this slightly larger decrease, especially since all participants experienced the 
decrease in Hcy. Additionally, participants with elevated depression scores experienced a 
slightly larger reduction in Hcy compared to participants with normal BDI scores.   
Clinically significant change is usually defined as a meaningful degree of change that 
resulted from an intervention or treatment (Kazdin, 2003, p. 692).  However, any amount of 
change may mean something depending on the type of problem, as well as the goals of the 
treatment.  When dealing with health issues, such as the reduction of Hcy, even a small decrease 
may be important because Hcy has been associated with heart disease development.  
Interestingly, absence of change is important in that it offers information about stability over 
time.      
Another interesting finding was that of the relationship between vitamin supplementation 
and psychological functioning defined by BDI scores.  Vitamin group participants had decreased 
BDI scores over time while placebo group participants were found to have increased BDI scores.  
We can infer that supplementation may improve psychological functioning, but it cannot be 
confidently concluded that it was vitamin supplementation that led to the improvement  in 
psychological functioning.  No conclusions can be made because results were statistically non­
significant. Also, BDI scores were not above the cutoff for mild clinical depression, meaning 
that the participants were generally of normal mental health and any improvements in their 
psychological functioning may not be clinically meaningful.  Although most of the results were 
statistically non-significant, meaning that the finding or difference cannot be confidently 
considered as unlikely due to chance, according to Cowles & Davis (2003), “any level of 
significance is a useful guideline and may provide a filter for making decisions about effects and 
variables to be further examined” (p. 381).    
Due to a small sample size, which was smaller than the recommended sample size to 
obtain significant statistical power, results were non-significant and therefore, no solid 
conclusions can be made about the findings.  Also, due to lack of clinically depressed 
participants, possible vitamin effects on psychological health were not as noteworthy as 
expected. The study also lacked participants with elevated Hcy levels, which could have 
contributed to non-significant effects of vitamins on Hcy.  Future studies should obtain a larger 
sample size that includes moderately to severely depressed participants, as well as participants 
with elevated Hcy levels. It may be that vitamin supplementation has a larger effect on these 
types of participants. Healthy middle-aged participants may not be as responsive to vitamin 
effects, in part, because they are less likely to have deficient vitamin levels in the blood.  Despite 
the lack of an extreme clinical sample, meaning that the sample was within the normative range 
of the variables examined, normative data is still useful as a criterion for determining clinical 
significance and as a comparison for problem domains (Kazdin, 2003, p. 691).   
The overarching goal of this project is to find more efficient and economical ways of 
reducing heart disease risk. In this particular study, the primary way of reducing heart disease 
risk that was promoted was reduction of Hcy.  However, Hcy is only one of many factors that 
contribute to heart disease and should not be the primary concern when taking preventative 
measures against development of heart disease.  Other factors such as diet, age, and level of 
physical activity should also be taken into consideration.  The immediate goal of this study was 
to find possible factors affecting Hcy, specifically psychological functioning and vitamin 
supplementation.  That goal was obtained by the statistical analyses performed.  However, no 
further conclusions about the role of Hcy reduction in heart disease prevention can be made 
confidently. 
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Table 1 
Mean and Standard Deviation of Variables of Interest for  
Vitamin and Placebo Group Participants Over Time 
         _____________Vitamin_____________     _____________Placebo_____________ 
Variables Pre-test Post-test Pre-test Post-test 
M SD M SD M SD M SD ____ 
Hcy 8.15 3.70 7.10 2.69 8.72 3.20 8.06 2.99 
B6 22.77 52.96 29.04 51.46 14.58 10.37 28.37 22.68 
B12  574.58 197.21 556.58 217.66 632.03 266.34 640.05 262.96 
Folate 19.57 5.33 20.62 4.54 18.85 5.30 19.89 4.74 
BDI 5.85 5.43 4.56 4.13 5.68 5.96 6.61 7.29 
LOT-R 12.41 4.31 10.59 4.04 12.80 4.90 11.73 5.99 
PSS-10 13.77 6.82 10.44 5.92 14.00 7.94 12.80 8.01 
POMS n/a 27.62 9.45 n/a 31.88 12.00 
Figure Caption 
Figure 1.  Change in mean Hcy levels of depressed and non-depressed participants. 
Figure 2.  Change in mean BDI scores of vitamin and placebo group participants over time. 
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Figure 1.  Change in Hcy levels of depressed and non-depressed individuals.  ANOVA indicated 
that pre-test differences in Hcy levels were largely different between participants.   
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Figure 2.  Change in mean BDI scores of vitamin and placebo group participants over time 
showed that mean BDI scores of vitamin group participants decreased and mean BDI scores of 
placebo group participants increased. 
